
Validea's guru fundamental report indicates that ELEVANCE HEALTH INC (ELV) receives a 79% rating based on its Low PE Investor model, which is based on the investment strategy of John Neff. The analysis, which focuses on firms with persistent earnings growth trading at a discount, highlights strengths in ELV's P/E ratio, EPS growth, future EPS growth, sales growth, and free cash flow, but identifies weaknesses in total return/PE and EPS persistence. Neff's historical performance, outperforming the S&P 500 by 3.1% annually from 1964 to 1995, underscores the potential value in this investment approach.
Elevance Health Inc. (ELV) has been analyzed by Validea's guru fundamental report, achieving a 79% rating based on the Low PE Investor model, which emulates John Neff's strategy. This strategy seeks firms with persistent earnings growth trading at a discount, yet notably, ELV failed the 'EPS Persistence' criterion despite passing 'EPS Growth' and 'Future EPS Growth'. The 79% rating positions ELV just below the 80% threshold that typically signifies the model has 'some interest' in a stock, indicating it is approaching this level of consideration. ELV, a large-cap growth stock in the Insurance (Accident & Health) sector, passed other key fundamental tests including P/E Ratio, Sales Growth, and Free Cash Flow. However, alongside 'EPS Persistence', the stock also did not meet the criterion for 'Total Return/PE'. The overall sentiment regarding this specific assessment is neutral-to-mixed (general sentiment score 0.05), though ELV's ticker-specific sentiment is mildly positive (0.4), reflecting this balance of strengths and weaknesses under a historically successful investment framework; Neff's Windsor Fund notably outperformed the S&P 500 by 3.1 percentage points annually from 1964 to 1995.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment